Previous clinical trials have demonstrated that IL-3 can elevate peripheral platelet and neutrophil counts and mitigate chemotherapy-induced myelosuppression in cancer patients suffering from bone marrow failure and undergoing chemotherapy. The gene discussed is IL3; the disease is cancer.